Three in Medical Technology

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application on proprietary, naturally occurring, resected hu...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to ...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

- Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R) - NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. presented results of a new study, "Effects of 1, 2, or 3 Prandial Injections of ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data - CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...

Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder

Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) today announced positive results from a phase three clinical trial of NUVIGIL(R) (armodafinil) Tablets [...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presen...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced positive pr...

Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

Long-term benefits of preventing heart attacks highlighted in new study presented at global health outcomes meeting ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart ...

First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies

Multi-Disciplinary Oversight Panel Includes American Brachytherapy Society, American Society of Breast Surgeons and American College of Radiation Oncology SUNNYVALE, Calif., June 24 /PRNewswire/ -- Xoft, Inc. today announced the launch and of the EXIBT Study (El...

Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO'08

SAN DIEGO, June 18 /PRNewswire/ -- Kansas researchers and companies excel in the human health biosciences, and $3.7 million in new Kansas Bioscience Authority (KBA) investments in that sector will support cutting-edge innovations for the treatment of cancer, HIV, and osteoporosis, as well as i...

Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

Company to Continue Focus on Pipeline and Haptoglobin Diagnostic Assay MONTVALE, N.J., June 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI ) today announced data from three Phase 2 trials (Trials 201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a estab...

Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer

MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will ...

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

- Phase II study extension shows 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment with oral FTY720 - New data demonstrate 89% of patients free from active brain lesions - the injury caused by MS - three years after starting treatment - MS, ...

Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico

MONTERREY, Mexico, March 20 /PRNewswire/ -- Optimum Health Regeneration Center announced the successful treatment of an American family treated for pain management and impaired mobility. This New Mexico family, ranging in age from 52 to 78, all recorded significant improvements in reduced pain...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial o...

TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY

New AcuCare Programs Automate the Interface between Health Assessments for Patients and the Generation of Customized Care Treatment Plans AUBURN, Calif., Jan. 22 /PRNewswire/ -- TCS Healthcare Technologies, an industry leader in the development of medical management software applications th...

Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year

DALLAS, Nov. 1 /PRNewswire-USNewswire/ -- Death resulting from influenza, often referred to as "the flu," is more common among individuals with heart disease than among patients with any other chronic medical condition. However, according to a new nationwide survey of heart disease patients co...

Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007

- Presentations on long-term safety and cardiovascular safety of nebulized formoterol fumarate and safety/ efficacy of concomitant use with tiotropium for treatment of COPD - NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL ), announ...

Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week

Variety of new applications spans paleogenomics, paired-end mapping, and gene expression analysis BRANFORD, Conn., Oct. 2 /PRNewswire/ -- 454 Life Sciences, a Roche company, is the subject of three ground-breaking studies published last week in Science, all of which empl...

ViroPharma to Present at Three Upcoming Healthcare Conferences

EXTON, Pa., Aug. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that Vincent Milano, vice-president, chief operating officer and chief financial officer of ViroPharma, will present at the Thomas Weisel Partners 2007 Healthcare Conference at 8:00 A.M. ET o...

EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds

Multiple Mechanisms for Panzem NCD, MKC-1, and ENMD-1198 Highlighted at Oncology Drug Discovery Conference ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases,...

Data supporting three Antisoma programmes presented at AACR

LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces that preclinical data supporting three of its drugs are presented this week at the Annual Meeting of the American Association of Cancer Research (AACR). AS1404-Avastin-paclitaxel triple combination highly effective Antisoma's scientists ...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resection is Well Tolerated in Phase 2b Bladder Cancer Study IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced results of a Phase 2b study of EOquin, in non-invasive bladder cancer and ...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyses looking at factors contributing to successful treatment of ulcerative colitis (UC), were presented at Digestive Disease Week (DDW) this week. Both of these studies were funded by Procter & Gamble (P&G) Pharmaceuticals, Inc. Fin...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood Glucose Control and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study that showed BYETTA(R) (exenatide) injection sustained impr...

Regular Yoga Practice Is Associated With Mindful Eating

...rld-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please vi...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...drug in 2009; clinical trials already initiated on three drugs this year Expand pipeline by moving a...perations of $4.8 million and $5.5 million for the three and six months ended June 30, 2009, respectively, ...and a loss from operations of $5.2 million for the three and six months ended June 30, 2008, respectively. ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...ient Phase 2 clinical trial was to assess safety and evaluate the effect of three doses of BA058 on bone formation markers and on lumbar spine and femoral ne...inued throughout the study. Treatment was randomized to Forteo(R) or one of three doses of BA058 (20, 40, or 80 micrograms), or matching placebo. The study's...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...e group administered Labopharm's trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improvements versus placebo in all three quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night". The inci...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ktar preclinical and clinical development programs. Revenue for the three month period ended June 30, 2009 was $13.0 million compared to revenue of $... information) (unaudited) three Months Ended Six Months Ended June 30, ...

Study Shows Brain Fitness can Save Medicare Billions

...endent and Vital Elderly (ACTIVE) study. There were 2,802 healthy adults, aged 65 and older, enrolled in the study. The participants were divided into three intervention groups and a no contact control group. The intervention groups received classroom training in reasoning or memory strategies or took part...

Scientists Discover Origin of Malaria

...d wild-born captive chimpanzees in Cameroon and Ivory Coast. In Cameroon researchers collected samples from chimpanzees during routine health exams in three different wildlife sanctuaries. They were primarily wild-born animals brought to the sanctuaries after being confiscated by authorities or abandoned b...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

...two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... KLRI's Director and President. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial compared conjugated equine estrogen (CEE) with three different CEE-progestin combinations and placebo in 875 healthy, postmenopausal women, aged 45 to 64. KLRI has found that other trial results used by ...